From NASH patent application published 4/30/2025
Post# of 152202
(Total Views: 361)
Posted On: 05/02/2025 2:53:01 AM
From NASH patent application published 4/30/2025
".....a CCR5 binding agent, such as leronlimab-bound CCR5 prevents transcellular migration, which is likely a key mechanism by which a CCR5 binding agent, such as leronlimab, restores vessel integrity and restitution of the immune function."
Restores.
Vessel.
Integrity.
___
In addition to stopping the Metastatic Process, which kills 90% of all cancer patients & Angiogenisis.
".....a CCR5 binding agent, such as leronlimab-bound CCR5 prevents transcellular migration, which is likely a key mechanism by which a CCR5 binding agent, such as leronlimab, restores vessel integrity and restitution of the immune function."
Restores.
Vessel.
Integrity.
___
In addition to stopping the Metastatic Process, which kills 90% of all cancer patients & Angiogenisis.
(5)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼